Clinical trial · Interventional
Exercise Training in Childhood Cancer
Get Strong to Fight Childhood Cancer: An Exercise Intervention for Children and Adolescents Undergoing Anti-Cancer Treatment
NCT05289739CI-TRIAL-00102754FORTEecompletedN/AClinicalTrials.gov clinicaltrialsProvenance
- Source
- ClinicalTrials.gov
- Retrieved
- Sep 8, 2026
- Layer
- normalized (units and labels harmonized; values unchanged)
- Run
- ING-CLINICALTRIALS-20260908-000001
Summary
Brief summary (as posted)
The purpose of this multicenter study is to evaluate a personalised and standardised exercise intervention for children and adolescents undergoing anti-cancer treatment.
Conditions
Conditions (1)
Free-text conditions as registered, with the CancerIndex entity they were reconciled to and the match type.
| Condition (as posted) | Mapped entity | Match | Confidence |
|---|---|---|---|
| Pediatric Oncology | — | UNRESOLVED | — |
Interventions
Interventions (1)
| Intervention | Type | Mapped drug | Match |
|---|---|---|---|
| Exercise training | Behavioral | — | UNRESOLVED |
Design
Arms and outcomes
Arms (2)
- type
- EXPERIMENTAL
- label
- Exercise group
- description
- Usual medical care + supervised exercise training during intensive medical treatment
- interventionNames
- Behavioral: Exercise training
- type
- NO_INTERVENTION
- label
- Control group
- description
- Usual medical care
Primary outcomes (1)
- measure
- Change in the score of Cancer-related fatigue during the intervention, after the intervention, and over a 1-year follow-up period compared with baseline
- timeFrame
- pre-intervention; bi-weekly during the intervention (up to 10 weeks); end of intervention (assessed up to 10 weeks); 12 weeks after the end of intervention; after intensive cancer treatment; 15 months after the end of intervention
Eligibility
Eligibility (as posted)
- Sex
- All
- Minimum age
- 4 Years
- Maximum age
- 21 Years
Show eligibility criteria text
Inclusion criteria: * First/initial diagnosis of a primary oncologic disease according to the International Classification of Childhood Cancer (ICCC), requiring chemotherapy and/or radiation therapy or First/initial diagnosis of a relapsed oncologic disease according to the International Classification of Childhood Cancer (ICCC), requiring chemotherapy and/or radiation therapy or First/initial diagnosis of a secondary oncologic disease according to the International Classification of Childhood Cancer (ICCC), requiring chemotherapy and/or radiation therapy * Planned or started anti-cancer treatment (chemo- and/or radiotherapy) at one of the recruiting centres of the FORTEe trial * The patient is assessed by the treating team (pediatric oncologist, exercise professional etc.) as suitable to participate in the trial, e.g. due to medical or psychological reasons. * Existing informed consent (or assent) to participate in the study * The patient (and the legal guardian) has/have sufficient knowledge of the respective national or English language so that it is possible to carry out the informed consent as well as interviews (in age-appropriate language). * The patient is not in a terminal phase of the disease. Exclusion criteria: * Oncologic disease (primary/relapsed/secondary) according to the International Classification of Childhood Cancer (ICCC), requiring neither chemotherapy nor radiation therapy or solely requiring surgery * Reasons that already exist or are foreseeable at the time of study enrolment, due to which the patient will not have access to the exercise intervention and/or to the pre-test and/or to the post-test (e.g. foreseeable or planned, permanent change of treatment centre) * The patient is assessed by the treating team (pediatric oncologist, exercise professional etc.) as unsuitable to participate in the trial, e.g. due to medical or psychological reasons. * After detailed information and, if necessary, having time to consider, the patient (≥ 16 years of age) did not agree to give written informed consent to participate in the trial. * The patient (and the legal guardians) has/have insufficient knowledge of the respective national or English language, so that it is not possible to carry out both the informed consent and interviews (in age-appropriate language). * The patient is in a terminal phase of the disease
References
Publications (2)
- DERIVEDSolera-Sanchez A, Marriott H, Windsor S, Straun K, Neu MA, Dreismickenbecker E, Lanfranconi F, Peli L, Wiskemann J, Bauer N, Spreafico F, Zardo W, Baader T, Wright P, Faber J, Watson E; FORTEe Consortium. The use of motion tracking technology to support an exercise intervention for children and young people with cancer: perspectives of users and healthcare professionals in the FORTEe trial. Front Pediatr. 2026 Jul 8;14:1879166. doi: 10.3389/fped.2026.1879166. eCollection 2026. PMID 42488233
- DERIVEDNeu MA, Dreismickenbecker E, Lanfranconi F, Stossel S, Balduzzi A, Wright P, Windsor S, Wiskemann J, El-Rajab I, Lucia A, Fiuza-Luces C, Mongondry R, Fridh MK, Spreafico F, Konda B, Kitanovski L, Heisserer B, Polak M, Baader T, Bloch W, Gotte M; Network ActiveOncoKids; Rizvi K; Youth Cancer Europe; Ruckes C, Paul NW, Faber J; FORTEe Consortium. Get strong to fight childhood cancer - an exercise intervention for children and adolescents undergoing anti-cancer treatment (FORTEe): Rationale and design of a randomized controlled exercise trial. BMC Cancer. 2025 Aug 7;25(1):1275. doi: 10.1186/s12885-025-14489-y. PMID 40775303